Dr. Christian B.Fulda


Múnich +

Dr. Christian Fulda focuses his practice on the pharmaceutical, biotechnology, and medical device industries. Christian advises on strategic and transformative projects and matters, drawing on his extensive operational experience with the legal issues that these heavily regulated industries face. Christian has been the lead on transformative M&A deals, bet-the-company litigation, and disruptive technological developments. His particular focus is industry convergence, including digital health, and he routinely carries out multijurisdictional projects. Christian is currently extensively involved with assisting clients in matters related to COVID-19, from licensing deals to regulatory matters and international trade such as import and export of personal protective equipment (PPE) and other restricted products.

Christian is a Fellow of the International Institute for Law and Medicine and a member of BIO Germany (Regulatory Affairs Committee and Healthcare Policy Committee), Licensing Executives Society Germany (Life Sciences Working Group), the Federal Association of Pharmaceutical Manufacturers (BAH), Forum MedTech Pharma, the Middle-European Society for Regulatory Affairs (MEGRA), and the German Institution of Arbitration (DIS).


  • Cardinal Health sells its Cordis business to Hellman & Friedman for approximately $1 billionJones Day advised Cardinal Health in connection with the divestiture of its Cordis business to Hellman & Friedman for approximately $1 billion.
  • Global pharmaceutical company seeks over $1 billion in ICC arbitration related to licensing agreementJones Day successfully represented a global pharmaceutical company seeking over $1 billion in a licensing agreement dispute over royalty payments and the application of U.S. Supreme Court decisions in Brulotte and Kimble, among other claims.
  • Astellas returns rights to Eligard® in Europe, Middle East, CIS, and Asia to TolmarJones Day represented Astellas Pharma Europe Ltd. in connection with a series of transactions, including the sale of related assets, in which Astellas returned its in-licensing rights to Eligard® (leuprorelin acetate for injectable suspension), a treatment for advanced prostate cancer, sold by Astellas in Europe, the Middle East, the Commonwealth of Independent States (CIS) and Asia, to Tolmar International Limited.
  • Wellington Partners, MIG GmbH & Co. Fonds 16, and Salvia GmbH invest €15 million in growth financing of Creative BalloonsJones Day represented Wellington Partners Life Sciences V, a leading European Venture Capital firm investing in early- and growth-stage Life Science companies, together with MIG GmbH & Co. Fonds 16 and Salvia GmbH, in connection with their €15 million growth investment in Creative Balloons GmbH, a specialist in researching and developing ultra-thin polyurethane (PUR) balloons for medical device applications, namely catheter manufacturing.
  • Astellas transfers DIFICLIR in Europe, Middle East, Africa, and selected CIS to Swiss Tillotts Pharma AG for €109 millionJones Day advised Astellas Pharma Europe Ltd. on the sale of distribution rights to the product "DIFICLIR" in Europe, Middle East, Africa, and selected Commonwealth of Independent States (CIS) countries to Swiss Tillotts Pharma AG for €109 million.
  • STERIS acquires Cantel Medical for $3.6 billionJones Day advised STERIS plc in its acquisition of Cantel Medical Corp, a global provider of infection prevention products and services primarily to endoscopy and dental customers, for $3.6 billion.
  • Junshi and Lilly to develop and commercialize antibodies for prevention and treatment of COVID-19 coronavirusJones Day represented Shanghai Junshi Biosciences Co., Ltd. in its strategic collaboration and license agreement with Eli Lilly and Company for the development, manufacturing, and commercialization of two antibodies for the prevention and treatment of the COVID-19 SARS-CoV-2 novel coronavirus.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Procter & Gamble acquires consumer health business of Merck KGaAJones Day advised The Procter & Gamble Company (“P&G”) in its €3.375 billion ($4.2 billion) acquisition of the worldwide consumer health business of Merck KGaA.
  • CVC Capital Partners acquires Teva's International Women's Health assets for $703 millionJones Day advised CVC Capital Partners in its $703 million acquisition of Teva Pharmaceutical Industries Ltd's International (non-US), Women's Health assets.
  • Cardinal Health acquires leading patient product portfolio from Medtronic for $6.1 billionJones Day advised Cardinal Health on the acquisition of Medtronic's Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1 billion in cash.
  • Astellas Pharma acquires Ogeda SA for €800 million (US$852 million)Jones Day advised Astellas Pharma Inc., a Japanese leader in the pharma industry, in its €800 million (US$852 million) acquisition of Ogeda SA, a privately owned Belgian drug discovery company.
  • RTI Surgical divests cardiothoracic closure business to A&E Medical Corporation for up to $60 millionJones Day advised RTI Surgical Inc. regarding the sale of its cardiothoracic closure business to A&E Advanced Closure Systems, LLC (A&E Medical), a cardiovascular medical device OEM and a portfolio company of Vance Street Capital LLC, for up to $60 million.
  • Essilor acquires Brille24Jones Day advised Essilor International in the acquisition of 100% of Brille24 GmbH, one of the leading online retailers of optical products in Germany.
  • XIO acquires Lumenis for approximately $510 million, $14 per share, in cashJones Day advised XIO Group in its acquisition of Lumenis Ltd., the world's largest energy-based medical company for surgical, ophthalmology, and aesthetic applications, for $14 per share in cash, for an aggregate purchase price of approximately $510 million.
  • Mainstay Medical completes IPO in first ever dual listing on regulated market of Euronext in Paris and Enterprise Securities Market of Irish Stock ExchangeJones Day assisted Mainstay Medical Limited, a global medical device company, in connection with its €18.8 million (US$26 million) initial public offering including the first ever dual listing on the regulated market of Euronext in Paris and the Enterprise Securities Market of the Irish Stock Exchange.
  • North American biotech company obtains dismissal of English Court proceedings in relation to ICC arbitrationJones Day acted for a North American biotech company in proceedings under sections 67 and 68 of Arbitration Act 1996 relating to the identity of the respondent to an ICC arbitration.
    • November 20, 2014
      December 4, 2014
      EMA Disclosure of Marketing Authorization Data
    • November 13/14, 2014
      Transparency: The Inevitable Emergence of an Epic Issue, panelist, Food & Drug Law Institute European Conference
    • October 6, 2014
      BioM-Forum: IPO in the US - a reality
    • September 24, 2014
      How to Align your Regulatory Pathway for Marketing Authorisation of your Drug with the CE marking of a Companion Diagnostic and How to Secure a Successful Companion Diagnostic Strategy, C5 EU Pharmaceutical Regulatory and Competition Conference
    • July 7, 2014
      How pharmaceutical companies can prepare for release of confidential data by EMA and national authorities, Infotag of the German Pharmaceutical Industry Association (BPI) on the EMA Disclosure Policies
    • June 6, 2014
      Litigation Strategies for Life Sciences Patents under the Unified Patent Court, panelist, Union-IP Congress, Workshop Life Sciences
    • May 19, 2014
      Developing IIS Contracts & Ensuring Corporate Investment Protection, 4th Annual EU Investigator Initiated Studies Conference, Q1 Productions
    • May 6, 2014
      The Continuing Expansion of Health Care Enforcement by U.S. and International Authorities: Key Developments and Implications for the Future
    • April 10. 2014
      Supplementary Protection Certificates (SPC), Recent Case Law of the Court of Justice of the European Union, Opportunities for patent term extensions for the pharmaceutical Industry, German Pharmaceutical Industry Association (BPI), Patent Day
    • March 20, 2014
      Jeopardizing Research Investments through Publication. Publication of commercially confidential information by regulatory authorities - advantage to competitors and risk for patent applications? German Pharmaceutical Industry Association (BPI), CEO Day
    • November 28, 2013
      Predictability and Manageability of the SPC System. An Industry Perspective. German Patent and Trademark Office, SPC Roundtable
    • July 15, 2013
      Europe's New Unitary Patent and Unfied Patent Court: Supplementary Protection Certificates Under the New System
    • June 25, 2013
      Product Liability for Medical Devices, Forum MedTech Pharma, Market Access for Medical Devices Workshop
    • April 12, 2013
      Companion Diagnostics - Regulatory and Reimbursement Aspects, Licensing Executives Society (LES) Meeting
    • January 28, 2013
      The Patent-Regulatory Interface in the EU, EU Pharmaceutical Regulatory Law Boot Camp
    • November 29, 2012
      Utilising Supplementary Protection Certificates (SPC) to Extend Your Patent Lifecycle, Biosimilars Forum 2012
    • October 18, 2012
      Panel Discussion on Personalized Medicine, Symposium "Biotec+ICT=New Business"
    • September 24, 2012
      Managed Access Programs: The Regulatory Environment in the EU & RoW, Managed Access Programs Workshop at the Outsourcing in Clinical Trials Conference
    • September 19, 2012
      Medical Devices: Product Safety and Product Liability in the US, Forum MedTech Pharma, Workshop Market Access USA
    • September 13, 2012
      Healthcare Reforms in Key European Markets and Impact on Diagnostics, 3rd EU Diagnostic Reimbursement & Market Access Conference
    • July 19, 2012
      Pricing and Reimbursement Considerations for Access Programs in Europe, 5th Annual Congress on Access Programs for Investigational and Pre-Launch Drugs
    • May 4, 2012
      Biosimilars - The European Regulatory Pathway, Licensing Executives Society (LES) Meeting
    • February 7, 2012
      Developing Drug & Diagnostic Combination Products in the EU, IVD Regulations and Performance Evaluations Conference
    • September 6, 2011
      Impact of Pharmaceutical Reimbursement Changes on Diagnostics, European Diagnostic Reimbursement & Market Access Conference
    • August 4, 2011
      EU Biotech and Pharma Regulations: The IP Angle, Jones Day Client Seminar on Global Patent Trends in Life Sciences
    • June 21, 2011
      European Perspectives on Nanotechnology: Seizing Opportunities, Protecting Technology, and Avoiding Risks
    • 2011
      Third party changes changes to IVD. The One Touch Ultra Case and Beyond, European Diagnostic Performance Evaluation and Regulatory Conference
    • 2010
      Nanotechnologies - Opportunities and Risks: The regulatory framework for nanotechnology in Europe, JDialog Jones Day Client Seminar
    • 2009
      Market Access for Pharmaceuticals - Impact on License Agreements, Licensing Executives Society (LES) Meeting
    • 2009
      Liberalisation of Pharmaceutical Marketing, BPI Bayern Presentation
    • 2009
      Liberalisation of Pharmaceutical Marketing, Jones Day Client Seminar
    • 2008 / 2009
      New Requirements for the Distribution of Medical Devices, Seminars for Clinical Professionals
    • 2008
      European Pharmaceutical Marketing, Jones Day Client Seminar
    • 2008
      European Pharmaceutical Marketing, BPI Nordrhein-Westfalia Seminar
    • 2007
      Regulatory Issues in Biotech Transactions, Bio-M